Back to today’s briefing

Story perspectives

FDA Panel Debates Antidepressants' Risks During Pregnancy

7/22/2025

32 7

Summary

Story summary

An FDA panel recently grappled with the safety of antidepressants during pregnancy, raising alarms about potential risks such as autism and birth defects. While some urged for a "black box" warning, others stressed the critical need to address maternal depression, highlighting a deep divide within the medical community on this pressing issue.

1 of 1

Story summary

An FDA panel recently grappled with the safety of antidepressants during pregnancy, raising alarms about potential risks such as autism and birth defects. While some urged for a "black box" warning, others stressed the critical need to address maternal depression, highlighting a deep divide within the medical community on this pressing issue.